GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Net Income From Continuing Operations

ZBIO (Zenas BioPharma) Net Income From Continuing Operations : $-128.97 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Zenas BioPharma's net income from continuing operations for the three months ended in Sep. 2024 was $-38.61 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2024 was $-128.97 Mil.

Zenas BioPharma Net Income From Continuing Operations Historical Data

The historical data trend for Zenas BioPharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Net Income From Continuing Operations Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23
Net Income From Continuing Operations
-119.28 -37.12

Zenas BioPharma Quarterly Data
Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only 35.61 -24.59 -27.80 -37.98 -38.61

Zenas BioPharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-128.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Net Income From Continuing Operations
Comparable Companies
NWBO TSHA ENGN GOSS CRDF TRML CDXS TERN ANNX RIGL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
1000 Winter Street, North Building, Suite 1200, Waltham, MA, USA, 02451
Website
https://www.zenasbio.com
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.